Table 1.
Vector treatment | Erythropoietin (mU/ml)a | Hematocrita |
---|---|---|
rAAV2/5.CMV.eGFP | 0 (n=6) | 46±2.5% (n=17) |
rAAV2/5.CMV.Epo | 91.6±37 (n=8) | 81±10.1% (n=9)b |
rAAV2/5.CMV.-EpoR76E | 67.2±89.4 (n=18) | 55±11.3% (n=23) |
Data represent means±SD.
Mice treated with rAAV2/5.CMV.Epo were phlebotomized routinely to keep hematocrit levels from exceeding 90%; no other treatment groups required this.